COMP <GO>
MDXG vs ABBV // EV/EBITDA & P/E VALUATION
MiMedx Group Inc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MDXG 9
— ABBV 4
▲ EV/EBITDA & P/E VALUATION LEADER: MDXG
LAST: $3.97 (+0.51%) • MKT CAP: $579.3M
valuation
6.7x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDXG VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDXG | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.60% | 70.20% | +12.40 | MDXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 47.20% | 29.00% | +18.20 | MDXG | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.7x | 33.3x | -26.60 | MDXG | /valuation <GO> |
| Free Cash Flow Yield | 12.77% | 3.47% | +9.30 | MDXG | /fcf-yield <GO> |
| Operating Margin | 15.30% | 24.60% | -9.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 11.60% | 6.90% | +4.70 | MDXG | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 8.60% | +11.40 | MDXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.45 | 5.33 | +1.12 | MDXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | MDXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.9 | 65.1 | -32.23 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.0x | 113.1x | -103.10 | MDXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $579.3M | $513.86B | -$513.28B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDXG REV | ABBV REV | MDXG GROSS % | ABBV GROSS % | MDXG FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $418.6M | $61.16B | 82.6% | 70.2% | $74.0M | $17.82B |
| FY 2024 | $348.9M | $56.33B | 82.8% | 70.0% | $66.2M | $17.83B |
| FY 2023 | $321.5M | $54.32B | — | — | $26.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDXG // BETA —
ABBV // BETA 1.15